HED-TRC
- Conditions
- Hereditary DementiaHereditary Dementia (Alzheimer's disease, Frontotemporal dementia, Lewy body dementia, Vascular dementia, Cerebral white matter dementia, etc.)D003704
- Registration Number
- JPRN-jRCT1031230633
- Lead Sponsor
- Yoshiki Sekijima
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 55
1. Provide written informed consent of their own free will from the patient or a representative.
2. 12 years or older at the time of informed consent.
3. Have a study partner that is willing to participate as a source of information and has approximately weekly contact with the participant (contact can be in-person, via telephone or electronic communication).
4. Approximately healthy without severe current or past medical history which hinder research participation.
5. Have sufficient eyesight and hearing to undergo neuropsychological examinations.
6. Have sufficient Japanese ability.
1. History within 3 months of psychosis, agitation, or behavior problem which interfere study protocol.
2. Have a history of alcohol or substance use disorder defined by DSM-V within 2 years.
3. In the unstable medical condition judged by the investigator that pose risks or that interfere research result or subject's performance. It includes uncontrolled hypertension, uncontrolled diabetes, clinically serious heart, lung, kidney, liver, endocrine, or systemic disease.
4. History of primary or recurrent malignant cancer within the past 3 years, except for non-melanoma skin cancer, removed squamous cell carcinoma, basal cell carcinoma, cervical intraepithelial neoplasia, or non-invasive prostate cancer with normal PSA after treatment.
5. With an ineligibility judged by the principal investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.